Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,650 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Non-Small Cell Carcinoma Clear all
Completed Phase 2 Interventional

Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

NCT00449020
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 9, 2026, 5:11 PM EDT
Completed No phase listed Observational

Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs

NCT01346280
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III), Rectal Cancer (Stage III)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,079 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 1 Interventional

Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00907179
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LBH 589, Pemetrexed
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 9, 2026, 5:11 PM EDT
Not listed Phase 3 Interventional

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

NCT00246727
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Selected Vegetable and Herb Mix
Drug
Lead sponsor
Sun Farm Corporation
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 9, 2026, 5:11 PM EDT
Not listed No phase listed Observational

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

NCT05826756
View directory record Official record
Conditions
Lung Cancer Patients, Caregivers
Interventions
There are no interventions in this study. All participants complete online surveys.
Other
Lead sponsor
LUNGevity Foundation
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 9, 2026, 5:11 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Cemiplimab-Rwlc
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:11 PM EDT
Recruiting Phase 2 Interventional

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446
View directory record Official record
Conditions
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

NCT02403895
View directory record Official record
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
Open-label AZD2014, paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Bevacizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT03050554
View directory record Official record
Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
Avelumab, SBRT
Drug · Radiation
Lead sponsor
Andrew Sharabi
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 9, 2026, 5:11 PM EDT
Recruiting No phase listed Observational

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

NCT07339254
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 9, 2026, 5:11 PM EDT
Withdrawn Phase 2 Interventional

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141
View directory record Official record
Conditions
Lung Cancer
Interventions
BIBW 2992 (Afatinib)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

NCT01511081
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

NCT03131037
View directory record Official record
Conditions
Lung Cancer
Interventions
CAN-2409 + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer

NCT00819728
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Docetaxel, Irinotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 1 Interventional

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00369551
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis
Radiation · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 1Phase 2 Interventional

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

NCT00103831
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Oral Taxane
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 9, 2026, 5:11 PM EDT
Active, not recruiting Not applicable Interventional

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT01345851
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

NCT00866528
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 9, 2026, 5:11 PM EDT
Terminated Phase 3 Interventional Results available

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Pemetrexed Disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
268
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Antioch, California + 176 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 9, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
Interventions
Retifanlimab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Fresno, California • San Marcos, California • Santa Rosa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 9, 2026, 5:11 PM EDT